First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

被引：19
|
作者：
Roohullah, Aflah
Ganju, Vinod
Zhang, Faming
Zhang, Lei
Yu, Ting
Wilkinson, Kate
Cooper, Adam
de Souza, Paul
机构：
[1] South Western Sydney LHD, Liverpool, Australia
[2] Peninsula & Southeast Oncol, Frankston, Vic, Australia
[3] HanX Biopharmaceut Inc, Hangzhou, VA, Peoples R China
[4] Sydney Southwest Private Hosp, Liverpool, NSW, Australia
[5] St George Private Hosp, Liverpool, NSW, Australia
[6] St George Private Hosp, Kogarah, NSW, Australia
[7] Univ Western Sydney, Sch Med, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2517
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
    Ke, Hang
    Yang, Tao
    Zhang, Faming
    Chen, Cen
    Wang, Jingjing
    Liu, Jinping
    An, Xiaoyu
    Xiong, Lingxin
    He, Xianfei
    Zhang, Lei
    Li, Qi-Xiang
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [2] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [3] A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.
    Sanborn, Rachel E.
    Bordoni, Rodolfo Eduardo
    Fleming, Gini F.
    Khasraw, Mustafa
    Hawthorne, Thomas
    Thomas, Lawrence J.
    Rawls, Tracey
    Young, Diane C.
    Golden, Philip
    Keler, Tibor
    Yellin, Michael Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
    Ke, Hang
    Zhang, Faming
    Wang, Jingjing
    Xiong, Lingxin
    An, Xiaoyu
    Tu, Xiaolong
    Chen, Cen
    Wang, Yueying
    Mao, Binchen
    Guo, Sheng
    Ju, Cunxiang
    He, Xiangfei
    Sun, Ruilin
    Zhang, Lei
    O'Connor, Owen A.
    Li, Qi-Xiang
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
    Hang Ke
    Faming Zhang
    Jingjing Wang
    Lingxin Xiong
    Xiaoyu An
    Xiaolong Tu
    Cen Chen
    Yueying Wang
    Binchen Mao
    Sheng Guo
    Cunxiang Ju
    Xiangfei He
    Ruilin Sun
    Lei Zhang
    Owen A. O’Connor
    Qi-Xiang Li
    Scientific Reports, 13
  • [6] Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors
    Carneiro, Benedito A.
    Safran, Howard
    Beck, J. Thaddeus Thaddeus
    Hamid, Omid
    Spira, Alexander I.
    Savvides, Panos
    Gutierrez, Martin
    Zhao, Yujie
    Abbruzzese, James L.
    Ward, Jeffrey P.
    Weroha, Saravut John
    Harris, Loleta D.
    Kent, Sean
    Pierceall, William
    Skoura, Athanasia
    Zheng, Jenny
    Kern, Kenneth Alan
    Thomas, Jacob Stephen
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
    Horwitz, Steven M.
    Foran, James M.
    Maris, Michael
    Lue, Jennifer Kimberly
    Sawas, Ahmed
    Okada, Craig
    Feldman, Tatyana A.
    Sokol, Lubomir
    Mei, Matthew
    Flinn, Ian W.
    Villa, Diego
    Percival, Mary-Elizabeth M.
    Jagadeesh, Deepa
    Savage, Kerry J.
    Akilov, Oleg
    Diefenbach, Catherine S.
    Kim, Youn H.
    Lin, Gloria H. Y.
    Catalano, Tina
    Petrova, Penka S.
    Uger, Bob
    Molloy, Naomi
    Large, Kathleen
    Bruns, Ingmar
    Ansell, Stephen M.
    BLOOD, 2021, 138
  • [8] Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
    Horwitz, Steven M.
    Foran, James M.
    Maris, Michael
    Sawas, Ahmed
    Okada, Craig
    Feldman, Tatyana A.
    Minden, Mark D.
    Sokol, Lubomir
    Mei, Matthew
    Flinn, Ian W.
    Villa, Diego
    Percival, Mary-Elizabeth M.
    Jagadeesh, Deepa
    Savage, Kerry J.
    Akilov, Oleg E.
    Diefenbach, Catherine
    Kim, Youn H.
    Lin, Gloria H. Y.
    Catalano, Tina
    Petrova, Penka S.
    Uger, Bob
    Molloy, Naomi
    Large, Kathleen
    Shou, Yaping
    Ansell, Stephen M.
    BLOOD, 2020, 136
  • [9] A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors
    Naing, Aung
    Gelderblom, Hans
    Gainor, Justin F.
    Forde, Patrick M.
    Butler, Marcus
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Schellens, Jan H. M.
    Soria, Jean-Charles
    Taylor, Matthew H.
    Silva, Antonio P.
    Li, Zhonggai
    Bilic, Sanela
    Cameron, Scott
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345